| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.1 | 1.4 |
| Profit before tax | -5.3 | -5.0 |
| Net income | -5.3 | -5.1 |
| EPS (diluted, $ a share) | $-5.89 | $-71.05 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -26.0% |
|---|---|
| Operating margin | -328.0% |
10-Q filed with the SEC, NASDAQ: BIAF. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
bioAffinity Technologies, Inc.: key numbers
- Share price
- $2.00Close, Nov 16
- Market cap
- $3.64M
- Shares outstanding
- 1.82MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Commercial Physical & Biological ResearchSIC 8731
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from bioAffinity Technologies, Inc.
All →bioAffinity Technologies Business Update
bioAffinity Technologies announced a record monthly testing volume for its CyPath Lung test in October 2026, with 235 tests performed. This volume represents a 29% increase over October 2025 and is equivalent to approximately 45% of the total tests performed in the entire third quarter of 2026. The company attributed the growth to expanded sales efforts and increased adoption by both new and existing physicians.
bioAffinity Technologies Financial Results
bioAffinity Technologies reported its Q3 2026 financial results, highlighted by a 79% year-to-date increase in CyPath Lung testing revenue to $1.1 million. The company saw a 100% increase in test unit sales and an 89% increase in the number of ordering physicians compared to the prior year. Management noted continued momentum in commercialization and expansion of its government healthcare distribution network.
- Term
- Q3 2026
“Our third quarter results reflect the growing clinical adoption of CyPath® Lung as a vital tool for the early detection of lung cancer. With test unit sales doubling year-to-date and a significant increase in our physician base, we are seeing the direct impact of our commercial strategy and the clear need for noninvasive diagnostic solutions in the lung cancer care continuum.”
Maria Zannes, President and Chief Executive Officer
bioAffinity Technologies Business Update
bioAffinity Technologies announced it will participate in the Lung Cancer Initiative of North Carolina’s 'Battle of the Blues' event on November 5, 2026. The company will highlight its CyPath Lung noninvasive diagnostic test alongside physicians and patient advocates to promote early lung cancer detection during National Lung Cancer Awareness Month.
bioAffinity Technologies Clinical Trial Data
bioAffinity Technologies announced it will present positive research data at the CHEST 2026 annual meeting regarding its CyPath Lung test and a new investigational test for asthma and COPD-related lung inflammation. The presentation will focus on improving lung cancer risk stratification and managing pulmonary nodules using the company's noninvasive flow cytometry technology.
- Counterparty
- American College of Chest Physicians
bioAffinity Technologies Clinical Trial Data
bioAffinity Technologies announced it will present positive research data at the CHEST 2026 annual meeting regarding its sputum-based tests for lung inflammation. The data demonstrates the ability to detect multiple protein biomarkers and biologic drug targets for asthma and COPD using the company's flow cytometry and AI platform. The research aims to support a precision medicine approach for identifying patients who could benefit from specific biologic therapies.
- Counterparty
- American College of Chest Physicians
bioAffinity Technologies Capital Raise of $4M
bioAffinity Technologies entered into a securities purchase agreement with an institutional investor to raise approximately $4 million in gross proceeds. The offering consists of 116,545 shares of common stock and pre-funded warrants for 536,836 shares, priced at $6.122 and $6.115 respectively, alongside a private placement of unregistered warrants.
- Value
- $4M
- Counterparty
- institutional investor